Incyte Corporation $INCY Stake Reduced by Vinva Investment Management Ltd

Institutional investor decreased holdings in biopharmaceutical company by 14.5% in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd decreased its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 14.5% in the 3rd quarter, according to the company's most recent filing with the Securities and Exchange Commission. The institutional investor owned 169,732 shares of the biopharmaceutical company's stock after selling 28,673 shares during the period.

Why it matters

Incyte is a major biopharmaceutical company focused on oncology and inflammation treatments, with its flagship product being the FDA-approved drug Jakafi. Changes in institutional investor holdings can signal shifts in market sentiment and future performance expectations for the company.

The details

Vinva Investment Management Ltd decreased its stake in Incyte Corporation by 14.5% in the third quarter of 2026, selling 28,673 shares. The institutional investor now owns 169,732 shares, or approximately 0.09% of Incyte's outstanding stock. Several other hedge funds also made changes to their Incyte positions during the quarter, with some increasing and others decreasing their holdings.

  • Vinva Investment Management Ltd decreased its Incyte holdings in the 3rd quarter of 2026.

The players

Vinva Investment Management Ltd

An institutional investor that decreased its stake in Incyte Corporation by 14.5% in the third quarter.

Incyte Corporation

A biopharmaceutical company focused on oncology and inflammation treatments, with its flagship product being the FDA-approved drug Jakafi.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Incyte holdings by a major institutional investor could signal a shift in market sentiment around the company, though the overall reasons behind the move are unclear. Investors will likely continue to monitor Incyte's financial performance and pipeline developments to gauge the company's future prospects.